

**Supplemental Table S4.** Unadjusted and adjusted hazard ratios showing associations between demographic and clinical characteristics with COVID-19 death in the general population cohort

Variable	Unadjusted HR (95% CI)	P-value <sup>a</sup>	Adjusted HR (95% CI)	P-value <sup>a</sup>
<b>Demographics</b>				
Age (years)	1.075 (1.074, 1.076)	<.0001	1.047 (1.046, 1.049)	<.0001
Male vs. Female	1.25 (1.21, 1.29)	<.0001	1.43 (1.38, 1.48)	<.0001
Gender Unknown/Missing vs. Female	0.95 (0.24, 3.80)	.94	3.52 (0.88, 14.08)	.075
Asian vs. White	0.35 (0.30, 0.39)	<.0001	0.71 (0.62, 0.81)	<.0001
Black vs. White	1.67 (1.60, 1.75)	<.0001	1.21 (1.15, 1.27)	<.0001
Hispanic vs. White	0.95 (0.90, 1.007)	.089	1.02 (0.97, 1.08)	.39
Race unknown/missing vs. White	0.41 (0.38, 0.44)	<.0001	1.04 (0.96, 1.12)	.34
Midwest vs. South	0.66 (0.63, 0.68)	<.0001	0.90 (0.86, 0.94)	<.0001
Northeast vs. South	0.86 (0.82, 0.91)	<.0001	0.80 (0.76, 0.85)	<.0001
West vs. South	0.43 (0.41, 0.46)	<.0001	0.80 (0.76, 0.85)	<.0001
Region Other/Unknown vs. South <sup>b</sup>	0.008 (0.003, 0.022)	<.0001	0.02 (0.01, 0.06)	<.0001
<b>COVID-19 treatment</b>				
COVID-19 outpatient treatment	1.51 (1.35, 1.70)	<.0001	1.87 (1.66, 2.10)	<.0001
COVID-19 inpatient treatment	32.28 (30.14, 34.56)	<.0001	19.46 (17.83, 21.23)	<.0001
Tixagevimab/cilgavimab treatment <sup>b,c</sup>	/	/	/	/
<b>Comorbidities</b>				
Current/former smoker vs. Never smoker	2.72 (2.58, 2.88)	<.0001	1.42 (1.34, 1.50)	<.0001
Smoking status unknown vs. Never smoker	0.92 (0.87, 0.97)	.001	1.29 (1.22, 1.36)	<.0001
Previous COVID-19 infection	0.72 (0.68, 0.76)	<.0001	0.28 (0.27, 0.30)	<.0001
At least one COVID-19 vaccination	0.053 (0.049, 0.058)	<.0001	0.08 (0.07, 0.09)	<.0001
Asthma	1.47 (1.38, 1.57)	<.0001	0.99 (0.92, 1.05)	.67
Autoimmune	2.28 (2.17, 2.40)	<.0001	1.01 (0.95, 1.06)	.85

Cancer	3.46 (3.30, 3.63)	<.0001	1.11 (1.06, 1.17)	<.0001
Cerebrovascular disease	4.74 (4.54, 4.96)	<.0001	1.08 (1.03, 1.13)	.002
Kidney disease	7.36 (7.11, 7.62)	<.0001	1.49 (1.43, 1.55)	<.0001
Liver disease	2.65 (2.46, 2.85)	<.0001	1.38 (1.28, 1.49)	<.0001
Lung disease	6.74 (6.50, 6.99)	<.0001	1.46 (1.40, 1.52)	<.0001
Diabetes	5.57 (5.39, 5.76)	<.0001	1.71 (1.65, 1.78)	<.0001
Disability	0.95 (0.86, 1.04)	.26	1.32 (1.20, 1.47)	<.0001
Heart disease	7.39 (7.14, 7.64)	<.0001	1.54 (1.48, 1.60)	<.0001
HIV	1.27 (0.93, 1.74)	.13	1.12 (0.82, 1.53)	.47
Primary immunodeficiency	3.94 (3.24, 4.79)	<.0001	1.46 (1.20, 1.78)	.0002
Mental health disorder	1.89 (1.79, 2.004)	<.0001	1.06 (0.995, 1.12)	.071
Neurologic	6.32 (5.96, 6.69)	<.0001	1.4 (1.32, 1.49)	<.0001
Obesity	2.25 (2.17, 2.33)	<.0001	1.17 (1.12, 1.21)	<.0001
Pregnancy	0.14 (0.093, 0.197)	<.0001	1.10 (0.75, 1.61)	.63
Solid organ transplant	8.12 (7.26, 9.08)	<.0001	1.92 (1.68, 2.19)	<.0001

HR = hazard ratio

<sup>a</sup> P-values calculated from Cox proportional hazards models.

<sup>b</sup> We were not able to estimate a hazard ratio and corresponding p-value due to zero outcome events in the exposed group.

<sup>c</sup> The IR of those unexposed to tixagevimab/cilgavimab was 13783/8813080.8 PY = 1.6 Deaths/1000PY; The IR of those exposed to tixagevimab/cilgavimab was 0/4399.2 = 0 Deaths/1000PY.